SAN FRANCISCO and VANCOUVER, British Columbia — August 25, 2025 — Leads & Copy — Jade Biosciences, Inc. (Nasdaq: JBIO), a biotechnology company focused on developing therapies for autoimmune diseases, announced its participation in upcoming conferences.
Jade will participate in the Cantor Global Healthcare Conference from September 3–5, 2025, with a fireside chat on Tuesday, September 3 at 3:20 p.m. ET. It will also participate in the Stifel Virtual Immunology and Inflammation Forum from September 15–16, 2025, with a fireside chat on Tuesday, September 16 at 1:00 p.m. ET. Additionally, Jade will participate in the 11th Annual World Medical Innovation Forum, hosted by Bank of America and Mass General Brigham from September 15–17, 2025, with a panel on Immunology – Creating the Next Blockbuster in I&I, Tuesday, September 16 at 4:40 p.m. ET. Members of the Jade management team will host one-on-one investor meetings during the conferences.
Live webcasts of the Cantor and Stifel fireside chats will be available on the Events & Presentations page of the Jade Biosciences website, with archived replays accessible for 90 days following the event.
Jade Biosciences is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL and is being developed for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics.
Priyanka Shah can be reached at Media@JadeBiosciences.com, IR@JadeBiosciences.com or 908-447-6134.
Source: Jade Biosciences
